

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089916 A1

(51) International Patent Classification⁷: A61P 3/10, A61K 38/28, 9/00

(21) International Application Number: PCT/IB02/01216

(22) International Filing Date: 8 April 2002 (08.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/288,732 4 May 2001 (04.05.2001) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KRASNER, Alan, Seth** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/089916 A1

(54) Title: METHOD OF PREVENTING TYPE 2 DIABETES WITH AEROSOLIZED INSULIN

(57) Abstract: Inhaled insulin can be used to prevent the progression of beta cell failure in Type 2 diabetes, thereby slowing the onset, or by stopping the onset indefinitely, or ameliorating the disease in patients in whom it is already established.

METHOD OF PREVENTING TYPE 2 DIABETES WITH AEROSOLIZED INSULINField of the Invention

This invention is directed to a method of preventing Type 2 diabetes, with
5 inhaled insulin, comprising administering, to a human patient in need of such
prevention, an effective amount of inhaled insulin. The method operates, *inter alia*,
by slowing or arresting the immunologically mediated progression of pancreatic beta
cell failure.

10 Background of the Invention

Diabetes mellitus is a serious metabolic disease that is defined by the
presence of chronically elevated levels of blood glucose. Classic symptoms of
diabetes mellitus in adults are polyuria and polydipsia together with elevated levels of
plasma glucose. Normal fasting plasma glucose concentrations are less than 110
15 milligrams per deciliter. In diabetic patients, fasting concentrations are found to be at
or above 126 milligrams per deciliter. In general, diabetes mellitus develops in
response to damage to, or to defects in, the beta cells of the pancreas.

Primary diabetes mellitus is classified as Type 1 diabetes (also called insulin-
dependent diabetes mellitus or IDDM) and Type 2 diabetes mellitus (also called non-
20 insulin dependent diabetes mellitus or NIDDM). Type I (juvenile onset or insulin-
dependent) diabetes is a well-known hormone deficient state, in which the pancreatic
beta cells appear to have been destroyed by the body's own immune defense
mechanisms. Patients with Type I diabetes mellitus have little or no endogenous
insulin secretory capacity. These patients develop extreme hyperglycemia. Type I
25 diabetes was fatal until the introduction of insulin replacement therapy some 70 years
ago -- first using insulins from animal sources, and more recently, using human
insulin made by recombinant DNA technology. The destruction of beta cells in Type
I diabetes leads to the inability to produce insulin, and thereby a chronic insulin
deficiency. To these types of patients, insulin is most commonly administered by
30 subcutaneous injection, typically into the abdomen or upper thighs.

Type 2 diabetes is characterized by insulin resistance, i.e., a failure of the
normal metabolic response of peripheral tissues to the action of insulin. In other
words, insulin resistance is a condition where the circulating insulin produces a
subnormal biological response. In clinical terms, insulin resistance is present when

normal or elevated blood glucose levels persist in the face of normal or elevated levels of insulin. The hyperglycemia associated with Type 2 diabetes can sometimes be reversed or ameliorated by diet or weight loss sufficient to restore the sensitivity of the peripheral tissues to insulin. Progression of Type 2 diabetes mellitus is

5 associated with increasing concentrations of blood glucose and coupled with a relative decrease in the rate of glucose-induced insulin secretion. Thus, for example, in late-stage Type 2 diabetes mellitus, there may be an insulin deficiency. There is evidence for an autoimmune pathology in a subset of type 2 diabetics, namely the subclass which has come to be known as "latent autoimmune diabetes in adults",

10 abbreviated as LADA.

The nature of the lesion of the pancreatic beta cells in Type 2 diabetes is not clear. Unlike the pancreatic beta cells in Type I diabetics, the beta cells of Type 2 diabetics retain the ability to synthesize and secrete insulin and amylin.

The timewise progressions of Type I versus Type 2 diabetes can (and usually 15 do) differ markedly. Youthful (e.g., pediatric) patients suffering from Type I diabetes may not have their condition diagnosed until after the bulk of pancreatic beta cells have been destroyed, thereby necessitating chronic insulin therapy. Usually, Type I progresses on the order of a couple of years before the pancreas has been damaged to the point that it no longer produces sufficient insulin to meet the patient's metabolic 20 needs.

The treatment of Type I diabetes thus necessarily involves the administration of replacement doses of insulin, administered by the parenteral route. In combination with the correct diet and self-blood glucose monitoring, the majority of Type I diabetics can achieve a certain level of control of blood glucose.

25 In contrast to Type I diabetes, treatment of Type 2 diabetes frequently does not require the use of insulin, and the condition itself can progress over several decades. Institution of therapy in Type 2 diabetes usually involves a trial of dietary therapy and lifestyle modification, typically for 6-12 weeks in the first instance. Features of a diabetic diet include an adequate but not excessive total calorie intake,

30 with regular meals, restriction of the content of saturated fat, a concomitant increase in the polyunsaturated fatty acid content, and an increased intake of dietary fiber. Lifestyle modifications include the maintenance of regular exercise, as an aid both to weight control and also to reduce the degree of insulin resistance. If after an adequate trial of diet and lifestyle modifications, fasting hyperglycemia persists, then

a diagnosis of "primary diet failure" may be made, and either a trial of oral hypoglycemic therapy or direct institution of insulin therapy will be required to produce blood glucose control and, thereby, to minimize the complications of the disease.

Type 2 diabetics who fail to respond to diet and weight loss may respond to therapy

5 with oral non-insulin hypoglycemic agents such as sulfonylureas or biguanides.

Insulin therapy, however, is used to treat other patients with Type 2 diabetes, especially those who have undergone primary dietary failure and are not obese, or those who have undergone both primary diet failure and secondary oral hypoglycemic failure.

10

Summary of the Invention

This invention provides a method of preventing Type 2 diabetes with inhaled insulin, comprising administering to a human patient in need of such prevention, an effective amount of inhaled aerosolized insulin. Thus the insulin itself is an

15 aerosolized, particulate insulin, and it is inhaled, that is, it is administered by the pulmonary (deep lung) route.

"Insulin" means the art-recognized polypeptide used in the treatment of diabetics in a substantially purified form, and also the various commercially available forms which include excipients. The term encompasses natural extracted 20 human insulin, recombinantly produced human insulin, insulin extracted from bovine and/or porcine sources, recombinantly produced porcine and bovine insulin, and mixtures thereof. The term "insulin" is also intended to encompass insulin analogs wherein one or more of the amino acids within the polypeptide chain has been replaced with an alternative amino acid and/or wherein one or more of the 25 amino acids has been deleted or wherein one or more additional amino acids has been added to the polypeptide chain. In general, such insulin analogs of the present invention include "super insulin analogs" wherein the ability of the insulin analog to affect serum glucose levels is substantially enhanced as compared with conventional insulin as well as hepatoselective insulin analogs which are more 30 active in the liver than in adipose tissue. The invention may employ an aerosolized inhaled insulin which is monomeric, such as insulin lispro.

"Inhaled insulin" means an aerosolized, wet or dry, particulate, insulin-containing formulation which is administered via the pulmonary route by having the patient "breathe" an insulin-containing aerosol into the lungs, generally by drawing the

aerosol through the mouth and into the lungs. The formulation can, for example, comprise dry particles inhaled from a dry powdered inhaler such as that available from Inhale Therapeutics Systems, San Carlos, CA. The inhaled insulin formulation can also be a particulate, insulin-containing formulation suspended in a propellant.

5 Alternatively, the formulation can be a wet aerosol, i.e., a liquid aerosol of the type produced from an aqueous solution of insulin by a liquid nebulizer system (see Laube, Journal of Aerosol Medicine, Vol 4, No. 3, 1991, and US Patent 5,320,094, herein incorporated by reference in their entirety). The exact aerosol formulation is not believed to be particularly critical, such that the powder can be in the form of a dry
10 powder or a wet insulin-containing aerosol of the type produced by a nebulizer, so long as the particle size, whether liquid or dry, is of a size which facilitates penetration to the deep lung, in which it is believed that the alveoli serve as the portals from the lungs to the blood. Generally, such a particle size is less than about 10 μm . "Inhaled insulin" is to be contrasted with "intranasally administered insulin" in which insulin is
15 administered within the nasal passages and is weakly absorbed into the bloodstream through the nasal mucosa.

Inhaled insulin, in this invention, is employed to "prevent" diabetes, "prevention" meaning that an insulin-containing aerosol can be administered to patients prior to the onset of clinically apparent Type 2 diabetes in order to delay that
20 onset by a period ranging anywhere from a few months or years, up to essentially permanently. In this mode of prevention, a physician will generally diagnose that a patient is at risk for developing Type 2 diabetes by diagnosing that the patient has any one or more of the following conditions which are considered "precursor states" signalling the future onset of actual Type 2 diabetes.

25 1. Impaired fasting glucose, meaning that the patient does not exhibit a normal fasting glucose concentration of less than 110 mg/dl nor does the patient exhibit a fasting concentration of 126 mg/dl or above. In this situation the patient is considered to have impaired fasting glucose, but is not outright diagnosable as diabetic.
30 2. Impaired glucose tolerance, i.e. a state in which the patient does not respond normally when administered a standard oral glucose tolerance test. Impaired glucose tolerance is defined as a glucose level between 140-199 mg/dl two hours after the oral intake of 75 grams of glucose.

3. Women with a history of gestational diabetes but who are not yet diabetic.

In this precursor state the female patient would qualify or be diagnosed as diabetic at one or more times during pregnancy, but would not be diagnosed as diabetic outside of pregnancy.

5 "Prevention" in this invention also means that a patient can be administered inhaled insulin to slow or even completely arrest the progression of Type 2 diabetes once it has become clinically apparent and/or after it has been diagnosed. That is, a patient may be diagnosed as having Type 2 diabetes in an early stage such that the administration of exogenous insulin to control sugar metabolism is not yet required.

10 Inhaled insulin may nonetheless be prescribed at this point, not to control glucose metabolism, but to slow and/or arrest the progression of the Type 2 diabetes through its immunological effects. In this regard, it is noted that Type 2 diabetes may in many cases be characterized by the gradual death of pancreatic beta cells over time through an immunological mechanism, i.e., by lymphocytes which slowly, over

15 many years and even decades, effect or aid in the destruction of pancreatic beta cells and thereby bring about the onset and progression of Type 2 diabetes. Administration of inhaled insulin is believed to act, *inter alia*, by suppressing the activity of such lymphocytes. Thus, some patients who take inhaled insulin may have the progression of their Type 2 diabetes slowed, with the advantage that such

20 patients can delay having to take insulin simply to metabolize glucose. Instead, such patients will be able to rely on diet, exercise, and/or non-insulin therapy for much longer than in the absence of inhaled insulin therapy. Other patients may have the progression of their Type 2 diabetes arrested, with the result that they may never need to take exogenous insulin to control their blood sugars.

25 It is preferred to administer inhaled insulin from the time that a patient is either diagnosed to be at risk (i.e. to exhibit one or more of the aforementioned precursor states) or diagnosed to actually have Type 2 diabetes, at least up to the time that exogenous insulin administration becomes required to aid in controlling sugar metabolism.

30 To obtain the benefits of inhaled insulin through its immunological effects of preserving pancreatic beta cells, it is preferred to commence the administration of inhaled insulin to a patient as far in advance as possible of having to chronically administer insulin to control glucose metabolism. This means that inhaled insulin would be administered starting when either a precursor state or the actual onset of

Type 2 diabetes is diagnosed by the physician. Even if Type 2 diabetes is not detected until later in its progression, say until after it has become necessary to administer insulin for glucose control, inhaled insulin can still be administered, to preserve or to at least slow the destruction of whatever beta cell function remains,

5 in addition to controlling blood sugar metabolism.

Thus, the invention provides the means to prevent Type 2 diabetes in patients who exhibit a precursor state indicating that they are at risk for developing this condition. As mentioned above, the immunological capability of inhaled insulin to prevent Type 2 diabetes is thought to be associated with inhaled insulin's ability to

10 preserve, or at least retard, the damage to pancreatic beta cells, which damage would otherwise lead to the onset and/or progression of Type 2 diabetes. The

capability for prevention also derives from inhaled insulin's ability to arrest or slow pancreatic beta cell damage once Type 2 diabetes onset has occurred.

To summarize, the "prevention" afforded by the present invention may 15 manifest itself in one or more of the following ways:

1. a slowing of the onset of Type 2 diabetes when it is detected prior to clinical onset. This will occur when a regimen of inhaled insulin is initiated immediately after detection of a precursor state, or at least before the actual clinical onset of Type 2 diabetes. In patients who have already had the onset of clinical 20 diabetes, in most if not all such patients, the condition will also be more stable in the sense that blood glucose levels fluctuate less and exhibit less variability relative to the fluctuations and variability occurring in the absence of inhaled insulin therapy. In addition, less non-inhaled insulin therapy (exercise, diet control and other non-inhaled insulin antidiabetic medications) would be required.

25 2. in some cases when a precursor state is detected prior to clinical onset, the progression to Type 2 diabetes can be prevented altogether, meaning that the patient will never require any form of diabetic therapy, including exercise, dietary control oral agents, or exogenous insulin administration, beyond that which is inhaled, to effect prevention.

30 3. a slowing, and in some patients the complete stoppage, of the progression of diabetes by inhaled insulin in patients in whom the condition is clinically apparent.

The invention is surprising in that it represents a total change to the current practice of treating clinical Type 2 diabetes through diet, exercise, and/or medications

which control the blood sugar supply through other than immunological means. As mentioned above, examples of non-insulin medications which can be used to control blood sugar levels are the sulfonylureas and biguanides, known to the art, which are employed to restore normal glucose via a variety of non-immunological mechanisms.

5

Detailed Description

A. Inhalers/Administration

Any inhaler known to the art may be used for this invention so long as it is capable of delivering a therapeutically effective dose of insulin to the deep lung. This 10 includes any device such as those which are classified as dry powder inhalers, nebulizers, and metered dose inhalers. Potentially useful are art-recognized inhalers such as those sold under the names Turbohaler (Astra), Rotahaler® (Glaxo), Diskus® (Glaxo), the Ultravent nebulizer (Mallinckrodt), the Acorn II nebulizer (Marquest medical Products), the Ventolin® metered dose inhaler (Glaxo), the Spinhaler® 15 powder inhaler (Fisons), or the like.

In a preferred embodiment, insulin is inhaled as a dry powder by means of a hand-held device such as that disclosed in any of US patents 6,089,228, 5,458,135, 5,775,320, 5,785,049, 5,740,794, and WO 93/00951, the full disclosures of which are herein incorporated by reference. Such devices are available from Inhale 20 Therapeutics Systems, San Carlos, CA.

B. Formulations

Any formulation which makes it possible to produce aerosolized forms of insulin which can be inhaled and delivered to a patient via the intrapulmonary route 25 can be used in connection with the present invention. Specific information regarding formulations which can be used in connection with aerosolized delivery devices are described within Remington's Pharmaceutical Sciences, A. R. Gennaro editor (latest edition) Mack Publishing Company. Regarding insulin formulations, it is also useful 30 to note Sciarra et al. [*Journal of Pharmaceutical Sciences*, Vol. 65, No. 4, 1976].

A variety of different insulin-containing aerosol formulations can be used in connection with the present invention. The active ingredient within such formulations is insulin which is preferably recombinantly produced human insulin, but which may include insulin extracted from animal sources. Further, the insulin may be an insulin

analog which is an analog of human insulin which has been recombinantly produced.

Although the insulin and/or analog may be present by itself as the sole active ingredient, the insulin may be present with an additional active ingredient such as a sulfonylurea. However, such sulfonylureas are generally administered separately in order to more closely control dosing and serum glucose levels.

5 Regardless of the active ingredient, there are several basic types of insulin formulations which can be used in connection with the present invention. All of the formulations include insulin, preferably with a pharmaceutically acceptable carrier suitable for intrapulmonary administration. In accordance with a first formulation, a 10 low boiling point, highly volatile propellant is combined with the active ingredient and a pharmaceutically acceptable excipient. The active ingredient may, for example, be provided as a suspension or dry powder in the propellant, or the active ingredient may be dissolved in solution within the propellant. Both of these formulations may be readily included within a container which has a valve as its only opening. Since the 15 propellant is highly volatile, i.e., has a low boiling point, the contents of the container will be under pressure. Thus, when low boiling point propellants are used, the propellants are held within a pressurized canister of the device and maintained in a liquid state. When the valve is actuated, the propellant is released and forces the active ingredient from the canister along with the propellant. The propellant will 20 "flash" upon exposure to the surrounding atmosphere, i.e., the propellant immediately evaporates. The flashing occurs so rapidly that it is essentially pure active ingredient which is actually delivered to the lungs of the patient. The "flashing" phenomenon which occurs with the use of low boiling point propellents may greatly increase the practicality of the present invention as compared with nebulizers or formulations 25 which do not use such propellants in that larger amounts of drug can be easily administered in a short period of time. Further, since the material being delivered to the lungs is essentially pure drug, it is easier to monitor and more closely control dosing which is a critical feature of the methodology of the present invention.

Accordingly, when using such a delivery device it is preferable to use low boiling point 30 propellants such as low boiling point chlorofluorocarbons or hydrocarbons, e.g., trichlorofluoromethane and dichlorodifluoromethane. As non-chlorofluorocarbon containing propellants are developed which are low boiling point propellants, their use in connection with the present invention will become apparent to those skilled in the art.

In accordance with a second formulation, the insulin is provided in a solution formulation. In this embodiment a dry powder is preferably dissolved in an aqueous solvent to create a solution which is moved through a porous membrane to create an aerosol for inhalation. Such solutions can be of the type which are made available

5 commercially for injection and/or other solutions which are more acceptable for intrapulmonary delivery. An example of a suitable solution for generating aqueous aerosols from a nebulizer is the 0.9% saline solution disclosed in Laube, US patent 5,320,094.

A preferred form for inhaled administration of insulin is as a dry powder.

10 Preferred insulin dry powders include those which are described in US patent 5,997,848 to Patton et al. Such insulin powders comprise free flowing particulates having a size selected to permit penetration into the alveoli of the lungs, generally being less than 10 μm in diameter, preferably less than 7.5 μm , most preferably less than 5 μm , and usually being in the range from 0.1 μm to 5 μm in diameter. The

15 aforementioned particle sizes generally apply to solid particles. It is also feasible to employ larger size particles which are aerodynamically light but which have a mean diameter much larger than 10 μm , say 5 to 30 μm . Such particles generally have a low tap density, less than 0.4 g/cm³, and a mean diameter between 1 and three microns. Such particles are disclosed in US patent RE37,053 E, and in PCT

20 published application WO 01/13891, both herein incorporated by reference. In any case, the insulin powder employed should be of a size that is adapted to penetrating to the deep lung where it can be absorbed through the alveoli.

Alternatively, amorphous insulins could be prepared by lyophilization (freeze-drying), vacuum drying, or evaporative drying of a suitable insulin solution under

25 conditions to produce the amorphous structure. The amorphous insulin so produced can then be ground or milled to produce particles within the desired size range. Crystalline dry powder insulins may be formed by grinding or jet milling of bulk crystalline insulin. The preferred method for forming insulin powders comprising

30 particulates in the desired size range is spray drying, where pure, bulk insulin (usually in a crystalline form) is first dissolved in a physiologically acceptable aqueous buffer, typically a citrate buffer having a pH in the range from about 2 to 9. The insulin is dissolved at a concentration from 0.01% by weight to 1% by weight, usually from 0.1% to 0.2%. The solutions may then be spray dried in conventional spray drying

equipment from commercial suppliers, such as Buchi, Niro, and the like, resulting in a substantially amorphous particulate product.

The dry insulin powders may consist essentially of insulin particles within the requisite size range and be substantially free from any other biologically active

5 components, pharmaceutical carriers, and the like. Such "neat" formulations may include minor components, such as preservatives, present in low amounts, typically below 10% by weight and usually below 5% by weight. Using such neat formulations, the number of inhalations required for even high dosages can be substantially reduced, often to only a single breath.

10 The insulin powders useful in the present invention may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration. Such carriers may serve simply as bulking agents when it is desired to reduce the insulin concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the insulin
15 compositions and to improve the dispersability of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the insulin and to improve handling characteristics of the insulin such as flowability and consistency to facilitate manufacturing and powder filling.

20 Suitable carrier materials may be in the form of an amorphous powder, a crystalline powder, or a combination of amorphous and crystalline powders. Suitable materials include carbohydrates, e.g. monosaccharides such as fructose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, cellobiose, and the like; cyclodextrins, such as 2-hydroxypropyl- β -cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the
25 like; (b) amino acids, such as glycine, arginine, aspartic acid, glutamic acid, cysteine, lysine, and the like; (c) organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, and the like; (d) peptides and proteins, such as aspartame, human serum albumin, gelatin, and the like; (e) alditols, such as mannitol, xylitol, and the like. A preferred group of carriers includes lactose, trehalose, raffinose, maltodextrins, glycine, sodium citrate, tromethamine hydrochloride, human serum albumin, and mannitol.

30 Such carrier materials may be combined with the insulin prior to spray drying, i.e., by adding the carrier material to the buffer solution which is prepared for spray

drying. In that way, the carrier material will be formed simultaneously with and as part of the insulin particles. Typically, when the carrier is formed by spray drying together with the insulin, the insulin will be present in each individual particle at a weight percent in the range from 5% to 95%, preferably from 20% to 80%. The 5 remainder of the particle will primarily be carrier material (typically being from 5% to 95%, usually being from 20% to 80% by weight), but will also include buffer(s) and may include other components as described above. The presence of carrier material in the particles which are delivered to the alveolar region of the lung (i.e., those in the requisite size range below 10 μm) has been found not to significantly interfere with 10 systemic absorption of insulin.

Alternatively, the carriers may be separately prepared in a dry powder form and combined with the dry powder insulin by blending. The separately prepared powder carriers will usually be crystalline (to avoid water absorption), but might in some cases be amorphous or mixtures of crystalline and amorphous forms. The size 15 of the carrier particles may be selected to improve the flowability of the insulin powder, typically being in the range from 25 μm to 100 μm . Carrier particles in this size range will generally not penetrate into the alveolar region of the lung and will often separate from the insulin in the delivery device prior to inhalation. Thus, the particles which penetrate into the alveolar region of the lung will consist essentially of 20 insulin and buffer. A preferred carrier material is crystalline mannitol having a size in the above-stated range.

The dry insulin powders useful in the present inventions may also be combined with other active components. For example, it may be desirable to combine small amounts of amylin or active amylin analogues in the insulin powders 25 to improve the treatment of diabetes. Amylin is a hormone which is secreted with insulin from the pancreatic β -cells in normal (non-diabetic) individuals. It is believed that amylin modulates insulin activity in vivo, and it has been proposed that simultaneous administration of amylin with insulin could improve blood glucose control. Combining dry powder amylin with insulin in the compositions of the present 30 invention will provide a particularly convenient product for achieving such simultaneous administration. Amylin may be combined with insulin at from 0.1% by weight to 10% by weight (based on the total weight of insulin in a dose), preferably from 0.5% by weight to 2.5% by weight. Amylin is available from commercial suppliers, such as Amylin Corporation, San Diego, Calif., and can be readily

formulated in the compositions of the present invention. For example, amylin may be dissolved in aqueous or other suitable solutions together with the insulin, and optionally carriers, and the solution spray dried to produce the powder product.

The dry powder insulin compositions of the present invention are preferably aerosolized by dispersion in a flowing air or other physiologically acceptable gas stream in a conventional manner. One system suitable for such dispersion is described in copending application Ser. No. 07/910,048, which has been published as WO 93/00951, the full disclosures of which are incorporated herein by reference. The full operation of such a device is disclosed therein.

10 A preferred dry powder formulation, particularly for use with the aforementioned inhaler, is disclosed in WO 98/16205 (the full text of which is herein incorporated by reference) as example 3. It consists of a dry powder made by spray drying a formulation containing 7.50 mg insulin, 1.27 mg mannitol, 3.38 mg sodium citrate, 0.026 mg sodium hydroxide, and 0.32 mg glycine per milliliter of deionized water, for a total solids concentration of 12.5 mg/mL at pH 7.3, the formulation being spray dried to produce a dry powder having an average particle size less than 5 μ m. The powder is delivered to the deep lung via an inhaler. The preferred mode of treatment with dry powder insulin is as described in the aforementioned US patent 5,997,848.

15

20 C. Tests

The tests used herein to assess the state of a patient, and whether or not a regimen of inhaled insulin is appropriate, are the well known, art-recognized measurement of fasting and/or random serum, plasma, or whole blood glucose measurements. Assessment of beta cell function can be accomplished using glucose tolerance tests, especially intravenous glucose tolerance testing. In this method, glucose concentrations and plasma or serum insulin concentrations (the latter usually measured by radioimmunoassay or related techniques) are sampled before and after the administration of a known amount of glucose orally or intravenously. There are known normal patterns of glucose/insulin response to glucose challenge. Subjects with beta-cell dysfunction due to diabetes precursor states or diabetes will generally exhibit abnormal glucose/insulin responses to glucose challenge. Laboratory methods for measuring glucose and insulin levels are widely commercially available.

As a less preferred alternative, C-peptide concentrations (measured by radioimmunoassay or related techniques) in the fasting state and/or after glucose challenge (oral or intravenous) can be used to assess the functional integrity of pancreatic beta cells.

5 The amount of insulin to be administered and the appropriate regimen will generally be determined by the attending physician. In general, when administering insulin in the form of an aerosol, as recombinantly produced human insulin plus excipients, a patient will be administered an amount of inhaled insulin in the range of 0.5 to 50 mg per day, usually 0.5 to 25 mg per day, usually in 1 to 4 individual dry
10 powder doses. The dosing event itself will usually include administering the required dose in one or more, usually 1 to 4, inhalations from a suitable inhaler or nebulizer. Regardless of the form in which the inhaled insulin is delivered, i.e., regardless of whether the insulin is delivered as a dry powder, as an aqueous aerosol produced by a nebulizer, or as a suspension in a propellant delivered from a metered dose inhaler,
15 a patient will be delivered an amount of insulin equivalent to between 1.5 and 150 units delivered systemically (1 mg of inhaled insulin being generally equivalent to about 3 Units (U) of systemically delivered recombinant human insulin). Insulin analogs which are superactive can be administered in substantially smaller amounts while obtaining substantially the same effect with respect to reducing serum glucose
20 levels.

Diabetes prevention induced by inhaled insulin can be demonstrated in animals predisposed to the development of spontaneous diabetes. A suitable animal test model is disclosed in Harrison et al (J. Exp. Med., 184: 2167-2174, 1996) in which semisealed boxes containing groups of eight Nonobese Diabetic
25 (NOD) mice were exposed to aerosolized recombinant human insulin by connection to a standard patient electric pump and a nebulizer. Other strains of mice and other species may also be appropriate for this purpose. In such animals, after inhaled insulin exposure, time to onset of hyperglycemia in inhaled insulin treated animals can be compared to that in control air-exposed animals. After a (usually
30 pre-determined) period of exposure, pancreatic histology can be evaluated for cellular inflammatory autoimmune activity. In vitro, reduced lymphocyte proliferative responses to autoantigens can be shown to correlate with reduced pancreatic lymphocytic inflammation. Examples of relevant autoantigens which can be used in these lymphocyte proliferation assays include: insulin, insulin denaturation products

or major epitopes, and related islet antigens. Cytokines (such as interleukin-4 and interleukin-10) levels can be measured in inhaled insulin vs control animals, and can be used to assess degrees of anti-inflammatory cellular immune responses.

What is claimed is:

1. A method of preventing immunologically mediated beta cell failure prior to or after the onset of Type 2 diabetes with inhaled insulin, comprising administering to a human patient in need of such prevention, an effective amount of 5 inhaled insulin.
2. A method as defined in claim 1, wherein said inhaled insulin is delivered in the form of aerosolized insulin wherein the aerosol is atomized from a solution.
3. A method as defined in claim 1, wherein said inhaled insulin is 10 administered as a dry powder.
4. A method as defined in claim 1, wherein said effective amount of inhaled insulin is delivered by a propellant as a solution or suspension of said insulin from a metered dose inhaler.
5. A method as defined in claim 1, wherein said inhaled insulin is 15 administered from the time that a patient is diagnosed to be either at risk or to actually have Type 2 diabetes up to the time that exogenous insulin administration becomes required to aid in controlling sugar metabolism.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/01216A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61P3/10 A61K38/28 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, SCISEARCH, MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199620 Derwent Publications Ltd., London, GB; Class B04, AN 1996-200301 XP002205922 abstract & US 5 506 203 A (AB ASTRA) 9 April 1996 (1996-04-09) column 2, line 48 - line 55 column 3, line 11 - line 12 claims 1-7 --- -/-	1-5
X		1-5

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

19 August 2002

Date of mailing of the international search report

29/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

van der Kooij, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/01216

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 16205 A (INHALE THERAPEUTIC SYST ; KUO MEI CHANG (US); FOSTER LINDA C (US);) 23 April 1998 (1998-04-23) page 6, line 22 - line 25 page 16, line 20 -page 17, line 3 page 18, line 5 - line 9 examples 1-7 ---	1-5
X	WO 96 32149 A (INHALE THERAPEUTIC SYST) 17 October 1996 (1996-10-17) table 1 example 1 claims 1,8 ---	1-5
X	US 6 098 615 A (LLOYD PETER M ET AL) 8 August 2000 (2000-08-08) column 6, line 26 - line 27 claims 1-9 ---	1-5
X	LAUBE BETH L ET AL: "Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients." JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 269, no. 16, 1993, pages 2106-2109, XP008005799 ISSN: 0098-7484 the whole document ---	1-5
X	LAUBE BETH L ET AL: "The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes." CHEST, vol. 114, no. 6, December 1998 (1998-12), pages 1734-1739, XP008005801 ISSN: 0012-3692 the whole document ---	1-5
X	JENDLE J H ET AL: "Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes." SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, vol. 56, no. 6, 1996, pages 555-561, XP008005800 ISSN: 0036-5513 the whole document ---	1-5
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/01216

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CEFALU, WILLIAM T. ET AL: "Inhaled human insulin treatment in patients with type 2 diabetes mellitus" ANNALS OF INTERNAL MEDICINE (2001), 134(3), 203-207 , XP008005861 abstract page 204, column 2, paragraph 3 ----	1-5
X	KLONOFF, DAVID C.: "Inhaled insulin" DIABETES TECHNOLOGY & THERAPEUTICS (1999), 1(3), 307-313 , XP008005851 the whole document -----	1-5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/01216

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-5 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/01216

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9816205	A 23-04-1998	US	6258341 B1	10-07-2001
		AU	734891 B2	28-06-2001
		AU	5083498 A	11-05-1998
		EP	0941067 A2	15-09-1999
		HU	0001108 A2	28-08-2000
		NZ	336171 A	29-06-2001
		WO	9816205 A2	23-04-1998
		US	6309671 B1	30-10-2001
		ZA	9709145 A	11-05-1998

WO 9632149	A 17-10-1996	AU	2369599 A	08-07-1999
		AU	703491 B2	25-03-1999
		AU	5482596 A	30-10-1996
		AU	702150 B2	18-02-1999
		AU	5482796 A	30-10-1996
		BR	9609497 A	02-03-1999
		CA	2218116 A1	17-10-1996
		CA	2218208 A1	17-10-1996
		EP	0866726 A1	30-09-1998
		EP	0825885 A1	04-03-1998
		JP	10509738 T	22-09-1998
		JP	11503731 T	30-03-1999
		WO	9632152 A1	17-10-1996
		WO	9632149 A1	17-10-1996
		US	6372258 B1	16-04-2002
		US	6423344 B1	23-07-2002
		US	5780014 A	14-07-1998
		US	6051256 A	18-04-2000
		US	6258341 B1	10-07-2001
		US	6309671 B1	30-10-2001
		US	6019968 A	01-02-2000

US 6098615	A 08-08-2000	US	5915378 A	29-06-1999
		US	5672581 A	30-09-1997
		US	5364838 A	15-11-1994
		US	6131567 A	17-10-2000
		US	6085753 A	11-07-2000
		US	5970973 A	26-10-1999
		US	5873358 A	23-02-1999
		US	6024090 A	15-02-2000
		US	5941240 A	24-08-1999
		US	6167880 B1	02-01-2001
		US	6408854 B1	25-06-2002
		US	6250298 B1	26-06-2001
		US	5743250 A	28-04-1998
		US	2001037805 A1	08-11-2001
		US	5888477 A	30-03-1999
		US	5884620 A	23-03-1999
		US	2001045213 A1	29-11-2001
		US	2002059932 A1	23-05-2002
		US	2002046750 A1	25-04-2002
		US	2002035992 A1	28-03-2002
		AU	685694 B2	22-01-1998
		AU	4194996 A	23-05-1996
		CA	2203129 A1	09-05-1996
		EP	0785713 A1	30-07-1997
		JP	10509606 T	22-09-1998
		WO	9613161 A1	09-05-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/01216

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 6098615	A	AU	6097794 A	15-08-1994
		DE	69428357 D1	25-10-2001
		DE	69428357 T2	18-04-2002
		EP	0700302 A1	13-03-1996
		ES	2163432 T3	01-02-2002
		WO	9416717 A1	04-08-1994